News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Chari A, Larson S, Holkova B, et al. Phase 1 trial of ibrutinib

Articles by Chari A, Larson S, Holkova B, et al. Phase 1 trial of ibrutinib

Study Summary: Ibrutinib Plus Carfilzomib for Relapsed or Relapsed/Refractory Multiple Myeloma

ByChari A, Larson S, Holkova B, et al. Phase 1 trial of ibrutinib,carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma [published online April 4, 2018]. Leuk Lymphoma. 2018:1-7. doi: 10.1080/10428194.2018.1443337.

October 18th 2018

Latest Updated Articles

$Study Summary: Ibrutinib Plus Carfilzomib for Relapsed or Relapsed/Refractory Multiple Myeloma$
Study Summary: Ibrutinib Plus Carfilzomib for Relapsed or Relapsed/Refractory Multiple Myeloma
October 18th 2018

Trending on AJMC

Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD

Across the US, Obesity Care Still Lacks an Owner

FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes

Aspirin's CRC Benefit Narrows to PIK3CA Exon 9/20 Mutations

Personalizing Relapsed Multiple Myeloma Therapy: Amandeep Godara, MBBS